On examination of GBM cells where CRISPR-mediated BMI1 overexpression was engineered, simvastatin was found to be equally effective in impairing cell viability independently of BMI1 expression levels (Figure 5E), while U1866A did elicit a negative impact on cell viability only upon pharmacological inhibition of BMI1, but not when BMI1 expression levels were increased (Figure 5F). The gene discussed is BMI1; the disease is glioblastoma.